<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30309222</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2005-9256</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer research and treatment : official journal of Korean Cancer Association</Title>                <ISOAbbreviation>Cancer Res Treat</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.4143/crt.2018.312</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">We investigated the clinical relevance and spectrum of BRCA1/2 mutations in Korean ovarian cancer (KoOC) patients.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">Two hundred seventy-nine KoOC patients were enrolled from three university hospitals between 2012 and 2017. Their peripheral blood samples were obtained for BRCA1/2 mutation analysis by direct sequencing. Clinicopathological characteristics were retrospectively reviewed, and spectrum analyses of BRCA1/2 mutation were assessed by systematic literature review.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Frequency of BRCA1/2 mutations was 16.5% in KoOC patients. BRCA1/2 mutations were significantly associated with family history of breast/ovarian cancer (p&lt;0.001), serous histology (p=0.044) and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV, p=0.018) but not with early age-of-onset (age &lt; 50, p=0.729). Literature review of BRCA1/2 mutations in KoOC patients found 111 (55 distinct) mutations with high proportion of Korean-specific mutations (24/55, 43.6%). Comparing the spectrum of BRCA1/2 mutation between KoOC and Korean breast cancer (KoBC) patients, the ratio of BRCA1-to-BRCA2 mutations was different, with BRCA1 (78.4%) being predominant in KoOC and BRCA2 in KoBC (59.2%). The most common mutation also differed between the two (c.3627insA of BRCA1 in KoOC and c.7480C&gt;T of BRCA2 in KoBC).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The clinical relevance of BRCA1/2 mutations in KoOC patients was confirmed but that of early age-of-onset was not. Possible inconsistency in the ratio of BRCA1-to-BRCA2 mutations and the most common mutation between KoOC and KoBC may probably suggest presence of mutation sequence-associated penetrance tendency in hereditary Korean breast and ovarian cancer (KoBOC). These data may provide insights for optimal genetic counseling and prophylactic treatment for at-risk relatives of KoOC patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kwon</LastName>                    <ForeName>Byung Su</ForeName>                    <Initials>BS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Byun</LastName>                    <ForeName>Jung Mi</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Hyun Joo</ForeName>                    <Initials>HJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jeong</LastName>                    <ForeName>Dae Hoon</ForeName>                    <Initials>DH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Tae Hwa</ForeName>                    <Initials>TH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shin</LastName>                    <ForeName>Kyung-Hwa</ForeName>                    <Initials>KH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Suh</LastName>                    <ForeName>Dong Soo</ForeName>                    <Initials>DS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Ki Hyung</ForeName>                    <Initials>KH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Cancer Res Treat</MedlineTA>            <NlmUniqueID>101155137</NlmUniqueID>            <ISSNLinking>1598-2998</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA1 genes</Keyword>            <Keyword MajorTopicYN="N">BRCA2 genes</Keyword>            <Keyword MajorTopicYN="N">Germ-line mutation</Keyword>            <Keyword MajorTopicYN="N">Koreans</Keyword>            <Keyword MajorTopicYN="N">Ovarian neoplasms</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30309222</ArticleId>            <ArticleId IdType="pii">crt.2018.312</ArticleId>            <ArticleId IdType="doi">10.4143/crt.2018.312</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>